201162-52-9

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl 8-benzyl-3,8-diaza-bicyclo[3.2.1]octane-3-carboxylate is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the formation of complex molecular structures with potential therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, tert-butyl 8-benzyl-3,8-diaza-bicyclo[3.2.1]octane-3-carboxylate serves as a valuable building block for the creation of new chemical entities. Its stable and non-reactive nature allows for its use in a wide range of chemical processes, facilitating the development of novel compounds with diverse applications.
Used in Bioactive Compound Preparation:
tert-butyl 8-benzyl-3,8-diaza-bicyclo[3.2.1]octane-3-carboxylate is also utilized in the preparation of bioactive compounds, where its unique structure can be leveraged to enhance the biological activity of the resulting molecules, potentially leading to new treatments and therapeutic agents.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 93428-56-9 8-benzyl-3,8-diazabicyclo[3.2.1]octane 
• 100-44-7 benzyl chloride 
• 98068-06-5 8-benzyl-3-propionyl-3,8-diaza-bicyclo[3.2.1]octane 
• 67571-93-1 3-propionyl-3,8-diazabicyclo<3.2.1>octane 

Downstream Products

• 201162-53-0 tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate 

Relevant academic research and scientific papers

Substituted diazabicycloalkane derivatives

Compounds of formula (I) [in-line-formulae]Z-Ar1—Ar2??(I) [/in-line-formulae] wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

Novel amides useful for treating pain

The present invention relates to compounds of formula (I) that useful in treating pain.

Novel amides useful for treating pain

The present invention relates to compounds of formula (I-VII) or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R6, R7 and R8 are defined herein. The present invention also relates to methods of trating pain using these compounds and pharmaceutical compositions including these compounds.

Mono- and disubstituted-3,8-diazabicyclo[3.2.1]octane derivatives as analgesics structurally related to epibatidine: Synthesis, activity, and modeling

A series of 3,8-diazabicyclo[3.2.1]octanes substituted either at the 3 position compounds 1) or at the 8 position (compounds 2) by a chlorinated heteroaryl ring were synthesized, as potential analogues of the potent natural analgesic epibatidine. When tested in the hot plate assay, the majority of the compounds showed significant effects, the most interesting being the 3-(6-chloro-3-pyridazinyl)-3,8-diazabicyclo[3.2.1]octane (la). At a subcutaneous dose of 1 mg/kg, 1a induced a significant increase in the pain threshold, its action lasting for about 45 min. 1a also demonstrated good protection at a dose of 5 mg/kg in the mouse abdominal constriction test, while at 20 mg/kg it completely prevented the constrictions in the animals. Administration of naloxone (1 mg/kg ip) did not antagonize its antinociception while mecamylamine (2 mg/kg ip) did, thus suggesting the involvement of the nicotinic system in its action. Binding studies confirmed high affinity for the αβ2 nAChR subtype (K(i) = 4.1±0.21 nM). nAChR functional activity studies on three different cell lines showed that 1a was devoid of any activity at the neuromuscular junction. Finally, due to the analogy in their pharmacological profile with that of epibatidine, compounds were compared from a structural and conformational point of view through theoretical calculations and high-field 1H NMR spectroscopy. Results indicate that all of them present one conformation similar to that of epibatidine.